We assessed whether the intravenous administration of nicorandil, an adenosine triphosphate (ATP)-sensitive K ϩ channel opener, exerts beneficial effect on microvascular function and functional and clinical outcomes in patients with acute myocardial infarction (AMI).
Coronary reperfusion by the use of thrombolysis and/or angioplasty has been established as an essential therapy of acute myocardial infarction (AMI) (1) (2) (3) . Recently, we and other investigators demonstrated that pharmacologic treatment, such as intracoronary verapamil or nicorandil and adenosine, in conjunction with coronary reperfusion, can enhance functional improvement of left ventricle in patients with AMI (4 -6) . Among them, several experimental studies stressed that nicorandil, which is a hybrid of adenosine triphosphate (ATP)-sensitive K ϩ channel opener and nitrates, can enhance the recovery of postischemic contractile dysfunction and reduces infarct size (7) (8) (9) (10) . This cardioprotective effect of nicorandil was documented in a clinically relevant model, where nicorandil was given after a sustained period of ischemia and continued throughout reperfusion (10) . The mechanism involved in the salutary actions of nicorandil are not known for certain. Contribution of reducing preload and afterload, anti-free radical and neutrophil-modulating properties, the opening of K ATP channels and the vasodilatation of the small coronary arteries have been postulated. Kitakaze et al. documented that nicorandil mimics the effect of ischemic preconditioning in canine hearts (11) . However, there is no clinical study that nicorandil, if administrated intravenously, can limit infarct size and improve functional and clinical outcomes compared to coronary reperfusion alone.
The goal of this study is to assess the effect of intravenous nicorandil on the functional improvement, left ventricular morphology, in-hospital complications and survival in patients with reperfused anterior wall AMI. We chose intravenous rather than intracoronary injection, because this approach is easy and can be widely accepted in clinical settings. To assess its mechanism of cardioprotection, we also studied its effect on coronary microvasculature with myocardial contrast echocardiography (MCE).
METHODS

Study population.
From February 1994 through November 1996, 90 patients who were admitted to the Coronary Care Unit of the Sakurabashi Watanabe Hospital for their first myocardial infarction of the anterior wall and presented Thrombolysis in Myocardial Infarction (TIMI) grade 0 or 1 flow (12) at initial coronary angiography were considered study population. The diagnosis of AMI was made on the basis of chest pain of Ն30 min duration, ST segment elevation of Ն2 mm in two contiguous electrocardiographic (ECG) leads and more than threefold increase in serum creatine kinase activities. Nine patients were excluded from analysis because of: inadequate image quality (four patients) and coronary stenosis Ͼ90% in another coronary artery (five patients). Therefore, this report is based on the remaining 81 patients. All patients underwent percutaneous transluminal coronary angioplasty and achieved successful coronary reflow (TIMI grade 2 or 3) within 12 h after the symptom onset. An investigator obtained written informed consent from each patient. The study protocol was approved by the hospital's Ethics Committee.
Protocol. Just after the diagnosis of AMI, we randomly divided patients into two groups, nicorandil and control groups. After the bolus injection of nicorandil (4 mg) (Sigmat, Chugai), it was continuously injected at 6 mg/h for 24 h followed by oral nicorandil 15 mg/day until the discharge (a mean of 28 days) in the nicorandil group. Other protocols were the same between the two groups. All patients underwent cardiac catheterization with the use of the femoral approach after the injection of 100 U/kg heparin. After the injection of 0.3 mg of nitroglycerine into the left coronary artery, we performed the coronary angiography and left ventriculography. Then, we injected 2 ml of sonicated ioxaglate (Hexabrix-360, Tanabe) containing microbubbles (mean size, 12 m) into the left coronary artery for MCE as previously described (13, 14) . We used a mechanical sector scanner (model SAL-38B, Toshiba; carrier frequency, 3.5 MHz or SONOS 100, Hewlett-Packard; carrier frequency, 2.5 MHz). We initiated imaging of the apical long-axis view about 10 s before the contrast injection and continued it for an average of 30 s with constant gain setting. Myocardial contrast echocardiography images were recorded on 1.25-cm videotape with a S-VHS recorder (model AG-7350, Panasonic). We repeated MCE with the contrast injection into the right coronary artery. We also performed MCE a mean of 16 min (10 to 24 min) after angioplasty.
After angioplasty, heparin was continued for 48 h and was adjusted to maintain the activated clotting time to Ͼ180 s. All patients were maintained on a regimen of aspirin or ticlopidine and coumadine. If required, oral nitrates, calcium antagonists, beta-adrenergic blocking agents diuretics and/or angiotensin-converting enzyme inhibitors were added and continued until the late stage examination. We continuously monitored a lead V 5 -equivalent ECG until a mean of 7 days after the infarction (range, 3 to 10 days) for detecting arrhythmia. We performed the two-dimensional echocardiography on admission and at days 2, 3, 7 and 21 of the AMI with a commercially available electrical sector scanner (SONOS 1500 or 2500, Hewlett-Packard, carrier frequency of 2.5 or 3.75 MHz) and recorded the images on 1.25-cm videotape with the same S-VHS recorder. The presence or absence of pericardial effusion was also evaluated. We repeated coronary angiography and left ventriculography at a mean of 25 days after the AMI (range, 24 to 29 days) by use of the right brachial approach.
Analysis of echocardiographic data. We analyzed echocardiograms with a commercially available off-line computer system (Color Cardiology Workstation, TomTec Imaging). The details of analysis were described elsewhere (13) (14) (15) . In brief, an operator who did not know patients' data selected echocardiographic images with the best delineation between contrast-enhanced and nonenhanced myocardium to determine risk area which was determined to be an area showing contrast defect in the prereflow MCE images. Only when the endocardial length of contrast perfusion defect after angioplasty exceeded a quarter of that of the risk area was myocardial reperfusion in the corresponding segment considered incomplete (MCE no reflow). Areas showing contrast defects were always successfully defined, and measurements of the size of the residual contrast defects were highly reproducible (13) . Left ventricular wall motion was evaluated at baseline and at follow-up (day 21) according to the previously reported method (13) . We scored 17 segments of the left ventricle using the following system: 3, dys/akinetic; 2, severely hypokinetic; 1, hypokinetic; 0, normal. We Ito et al. March 1, 1999:654-60 Cardioprotection in AMI defined a sum of segmental scores as wall motion score. Two independent observers who did not know clinical data determined the segmental score, and a third observer established consensus in cases of disagreement.
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Analysis of catheterization data. An angiographer blinded to patient' data analyzed the cinefilms in a random sequence. The right anterior oblique view of left ventriculograms at acute and convalescent stages was analyzed. Enddiastolic volume and ejection fraction were measured with the area-length method. The regional wall motion (standard deviation/chord) of the territory of the left anterior descending coronary artery was analyzed with the centerline method (16) . The percent diameter stenosis after angioplasty and at follow-up study was measured. Collateral channels were graded following Rentrop classification (17) .
In-hospital data collection. We followed up the patients for the occurrence of complications until the time of hospital discharge. We carefully collected data on clinically relevant in-hospital events (death from any cause and reinfarction) in the study forms. The type and frequency of ventricular arrhythmias were evaluated from monitor ECG in the catheter laboratory and in the Coronary Care Unit. Malignant ventricular arrhythmia was defined as ventricular tachycardia (a minimum of three consecutive beats of ventricular origin at a rate of Ͼ100 beat/min) and ventricular fibrillation found within 24 h after angioplasty. Congestive heart failure (CHF) was diagnosed based on the same clinical criteria as previously reported (18) . Early postinfarction angina was defined as angina pectoris observed within 7 days after the onset of the AMI. Late postinfarction angina was defined by angina pectoris found beyond 7 days after the AMI and was evaluated mainly by symptom-limited bicycle ergometer exercise test performed at a mean of 25 days after the AMI (range, 24 to 27 days). Pericardial effusion and cardiac tamponade were diagnosed based on clinical and echocardiographic findings. 
RESULTS
Forty patients received the intravenous and oral nicorandil, and were designated as the nicorandil group. The other 41 patients were served as the control group. There were no differences in age, gender, culprit lesion, time from the symptom onset to reperfusion, heart rate, blood pressure, frequency of non-Q wave AMI, collateral grade or risk factors between the two groups ( Table 1 ). There were also no differences in the in-hospital medications other than nicorandil between the two groups.
Complications and in-hospital prognosis. Table 2 compares in-hospital ischemic events between the two groups. The extension, early and late postinfarction angina, restenosis and reocclusion were rare, and their frequencies were comparable between the two groups. Table 3 summarizes in-hospital complications and survival of the two subsets. Frequency of malignant ventricular arrhythmias within 24 h after angioplasty was significantly higher in the control group than the nicorandil group. Pericardial effusion was observed more frequently in the control group than in the nicorandil group. Cardiac tamponade was not found in the nicorandil group, but it was observed in 10% of the control Data are presented number of patients (percent). Abbreviations: Early PIA ϭ postinfarction angina observed within 7 days after the onset of the infarction; Late PIA ϭ postinfarction angina observed after 7 days of the infarction (mainly detected by late stage bicycle ergometer test).
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group. Congestive heart failure was observed more frequently Յ3 days of the AMI in the control group than in the nicorandil group. Congestive heart failure, if it occurred, tended to last beyond 3 days of AMI in the control group, whereas it rarely lasted beyond 3 days in most of the nicorandil group. Relative risk for each in-hospital complication with nicorandil was equal to 0.31 or less. No patient in the nicorandil group died in the hospital. In contrast, 4 patients (10%) among the control group died, three patients of CHF and one patient of acute cardiac rupture.
Left ventricular function and morphology. Table 4 compares temporal changes in left ventricular (LV) global and regional function and LV end-diastolic volume index (LVEDVI) between the nicorandil and control groups. Wall motion score significantly decreased from baseline to follow-up study in both groups. However, the magnitude of reduction was significantly greater in the nicorandil group than in the control group. An increase in regional wall motion was significantly greater in the nicorandil group than in the control group. Whereas LVEDVI decreased in the nicorandil group, it increased in the control group. But this difference did not reach statistical significance.
We also analyzed LV functional and morphological outcomes in patients who underwent angioplasty less than 6 h after the symptom onset (Table 5) . In this population, the improvement in regional function, such as wall motion score and regional wall motion, was also significantly better in the nicorandil group than in the control group. Again LVEDVI decreased in the nicorandil group and increased in the control group, as was observed in the whole population of patients. However, this difference in changes in left ventricular volume reached statistical significance in this early reperfusion group.
Hemodynamics and microvascular integrity. Both systolic blood pressure and pulmonary capillary wedge pressure showed comparable value between the control and nicoran- Data are presented number of patients (percent). Presence or absence of VT or Vf were evaluated within 24 h after coronary reperfusion. Abbreviations: CHF ϭ congestive heart failure; CI ϭ confidence interval; Early ϭ within 3 days after the infarction; Late ϭ beyond third day after the infarction; VT ϭ ventricular tachycardia; Vf ϭ ventricular fibrillation. ) . However, the frequency of MCE no reflow in the nicorandil group was lower by Ͼ50% than that in the control group (15% vs. 33%, P Ͻ 0.05) (Fig. 1) . Relative risk for each MCE no reflow with nicorandil was 0.34. Therefore, the differences in the improvement in regional left ventricular function and frequencies of in-hospital complications between the control and nicorandil groups may be explained by the difference in the severity of microvascular damages.
DISCUSSION
Intravenous nicorandil and clinical outcomes. Improvement in regional LV function was significantly better in the nicorandil group than in the control group. Although CHF was observed with similar frequency on admission between two groups, it more frequently lasted beyond 3 days after angioplasty in the control group than in the nicorandil group. This better functional improvement in the nicorandil group should be explained by the lower incidence of MCE no reflow in this group. The no reflow phenomenon is located within the area of myocardial necrosis (19 -21) ; thus, the greater size of no reflow as in cases of MCE no reflow should imply the greater size of AMI; thus, it may take longer for the left ventricle to adapt to it. An increase in myocardial blood to the jeopardized myocardium with nicorandil would lead to the reduction of the infarct size. The difference in duration of CHF between the two groups may be explained this way.
Frequency of either pericardial effusion or cardiac tamponade was significantly lower in the nicorandil group than in the control group. Frequency of malignant ventricular arrhythmia was also significantly lower in the nicorandil group than in the control group. In the previous study, we also reported that the frequencies of pericardial effusion, cardiac tamponade and reperfusion arrhythmia are significantly higher in patients with MCE no reflow than in those with MCE reflow. The broad and extensive myocardial damage in cases of MCE no reflow may contribute to the occurrence of malignant ventricular arrhythmia, pericarditis or oozing rupture (18) . Thus, the lower frequencies of post-AMI complications in the nicorandil group should be explained by the lower incidence of MCE no reflow of this group.
Left ventricular remodeling is sometimes observed during the early convalescent period of AMI. Although this dilation appears to represent a compensatory mechanism for suppressed LV function, it sometimes profoundly damages LV function and affects patient prognoses. Although coronary reperfusion per se might have a beneficial effect of preventing LV dilation, a substantial population (19% to 42%) of patients still manifest significant LV dilation (22) (23) (24) . Among patients with reperfused AMI, we previously reported that MCE no flow can strongly discriminate patients with LV dilation from those with MCE reflow. This is because the sizable no reflow phenomenon indicates the presence of greater size of AMI.
In this study, LVEDVI decreased from acute to late stage of AMI in the nicorandil group, whereas it increased in the control group. This finding was more evident in patients who underwent angioplasty within 6 h after the symptom onset. This result may be explained by the lower frequency of MCE no reflow in the nicorandil group. In addition to the possible smaller size of AMI in the nicorandil group, success of coronary perfusion at microcirculation may enhance the healing process of infarct tissue. Reduction of LV load with nicorandil may play an additional role in the prevention of LV dilation, although the hemodynamic variables were not different between the two groups.
Comparison with previous studies. In the previous study (5), we injected verapamil into the infarct-related artery after angioplasty in patients with AMI. We observed a decrease in size of the no reflow phenomenon and an increase in contrast peak intensity, which imply improvement in the microvascular function. This was associated with better improvement in LV function than angioplasty alone. Recently, Sakata et al. reported that the single administration of intracoronary nicorandil after angioplasty improves microvascular function, which was associated with better recovery of postischemic myocardial function in patients with AMI (4). In these studies, verapamil or nicorandil was injected directly into the coronary artery only after the presence or absence of no reflow phenomenon was judged with MCE. In contrast with these studies, we continuously injected nicorandil intravenously in the present study, but a similar salutary effect was demonstrated.
This may be explained by the difference in the onset and duration of the drug administration. We initiated the intravenous nicorandil just after the diagnosis of AMI was established, and it was at least 30 min before angioplasty. This was because we considered it hard to deliver nicorandil into the whole risk area, once the no reflow phenomenon is established. In an experimental study, Villanueva et al. (25) documented that the size of no reflow is minimal at the moment of coronary reperfusion, and it increases until 15 min after reperfusion, at which point we usually evaluate the presence or absence of this phenomenon in the clinical setting. This result indicates that myocardial blood flow may once be present even in no reflow zone. In such an instance, nicorandil may be effectively delivered to the postischemic microvascular beds on the blood flow at reperfusion. Additionally, nicorandil may also be delivered to the risk area by collateral flow before coronary reperfusion.
We continued the intravenous injection of nicorandil at least 24 h followed by the oral administration. Several studies have demonstrated that the no reflow phenomenon may progress for several hours after coronary reperfusion (26, 27) . The continuous infusion of nicorandil may restrain the progression of microvascular damages.
Possible mechanisms. Several mechanisms were postulated to explain the direct cardioprotective effect of nicorandil. First, opening of the K ATP channel in the ischemic myocardium shortens the duration of the action potential and inhibits voltage-dependent Ca 2ϩ channels and Na ϩ / Ca 2ϩ exchange. Because Ca 2ϩ overload in myocyte causes cellular damage, the inhibition of these routes for Ca 2ϩ influx may largely contribute to cardioprotection. Second, nicorandil reduces neutrophil infiltration into the ischemic myocardium (8, 10) . It also attenuates the activity of neutrophil in a concentration-dependent manner (28) . This reduction may attenuate microvascular injury caused by neutrophil, leading to an increase in myocardial blood flow. The attachment and migration of neutrophil through inflamed vessels is dependent on shear rate, and an increase in shear rate due to an increase in microvascular flow may also reduce neutrophil recruitment. An increase in blood flow can enhance the functional improvement of stunned myocardium (29) . Third, this may be related to the hemodynamic effect that is characterized by a reduction of preload and/or afterload. Finally, the vessels Ͻ100 m are more sensitive to nicorandil than other size vessels (30) .
The characteristic of nicorandil to reduce infarct size when given after coronary occlusion is not shared by other K ATP channel openers. In fact, bimakalim exerts its protective effects so long as it is given before the onset of ischemia, whereas it has no beneficial effect when administrated only during the reperfusion period (31) (32) (33) . The difference between nicorandil and bimakalim can be explained only by supporting that a mechanism other than K ATP channel opening is responsible for the cardioprotective effect of nicorandil. This may be in part explained by its nitrates activity.
Limitations. We selected the maximal intravenous dose allowed for the treatment of unstable angina pectoris and the oral dose routinely used in patients with angina pectoris. The optimal dose and protocol of nicorandil may be different from the protocol of this study. Our analysis was based on a comparison of in-hospital complications and functional outcomes only; survival and quality of life in a longer follow-up period were not taken into consideration. The salutary effect of intravenous nicorandil has not been established in patients with an inferior or posterior wall AMI or a recurrent AMI.
Myocardial contrast echocardiography data should be considered in light of several limitations. First, our method depends on image quality. Second, contrast intensity is influenced by many factors, including the size and number of microbubbles, factors altering ultrasonic reflection such as gain setting, depth of penetration, incident angle, axial and lateral resolution, gray scale compression and the nonlinearity of echo amplitude signals.
Clinical implications. Assessment of microvascular perfusion with MCE seems to be essential in gaining further understanding of patients' outcome and of the relation between intervention and outcome, since MCE is a useful method available for assessment of microvascular integrity. The prompt assessment of both coronary anatomy and the quality of microvascular perfusion and hence myocardial viability may aid in decision making in individual patients. Our results indicated that the intravenous nicorandil partially restrains ischemic microvascular damages and, thereby, augments myocardial blood flow. This was associated with better functional and clinical outcomes than angioplasty alone. Thus, we should achieve and maintain not only the patency of the epicardial coronary artery but also that of coronary microvasculature with pharmacologic intervention to achieve an optimal myocardial salve in AMI. Myocardial contrast echocardiograhy provides a useful method to promptly evaluate the salutary effect of these drugs on coronary microcirculation.
